US 12,134,762 B2
Lymphovascular invasion bioreactor and methods of making and using same
David Brown, Durham, NC (US); and Gayathri Devi, Durham, NC (US)
Assigned to Duke University, Durham, NC (US)
Appl. No. 16/762,857
Filed by Duke University, Durham, NC (US)
PCT Filed Nov. 9, 2018, PCT No. PCT/US2018/060016
§ 371(c)(1), (2) Date May 8, 2020,
PCT Pub. No. WO2019/094710, PCT Pub. Date May 16, 2019.
Claims priority of provisional application 62/583,662, filed on Nov. 9, 2017.
Prior Publication US 2021/0171893 A1, Jun. 10, 2021
Int. Cl. C12M 1/42 (2006.01); C12M 1/00 (2006.01); C12M 1/12 (2006.01); G01N 33/50 (2006.01); G01N 33/574 (2006.01)
CPC C12M 35/08 (2013.01) [C12M 23/14 (2013.01); C12M 25/04 (2013.01); G01N 33/5017 (2013.01); G01N 33/57415 (2013.01)] 17 Claims
OG exemplary drawing
 
1. An in vitro 3-D lymphovascular system comprising:
(a) a fluid chamber comprising medium in liquid communication with a transwell and a fluid pump,
(b) the transwell comprising a permeable membrane separating a basolateral surface and an apical compartment of the transwell, wherein the apical compartment of the transwell comprises:
(i) lymphatic endothelial cells (LECs) seeded on the apical surface of the permeable membrane;
(ii) a layer of hydrogel above the seeded LECs layer, and
(iii) medium comprising tumor cells; and
(c) a fluid pump capable of creating steady-state flow rate of medium throughout the fluid chamber and transwell of the system.